Depression
News
FDA approves brexanolone for postpartum depression
Brexanolone, which will be marketed under the brand name Zulresso, is the first pharmacotherapy approved for treating postpartum depression.
Original Research
Effects of Insomnia and Depression on CPAP Adherence in a Military Population
Initial self-reported depression and insomnia prior to the diagnosis and treatment of obstructive sleep apnea with continuous positive airway...
News
fMRI might help differentiate MDD and bipolar disorder
Major depressive disorder and bipolar disorder appear to be associated with different underlying brain structures.
News
FDA approves intranasal esketamine for refractory major depressive disorder
Under the FDA-required REMS, prescribers must complete specific training; the drug must be adminstered in office to allow for patient monitoring...
Conference Coverage
ICU admissions raise chronic condition risk
Compared to non-ICU visitors, patients had greater risk of developing new chronic conditions after discharge.
Audio
Suicide: Igor Galynker
Dr. Igor Galynker is back to talk with Dr. Lorenzo Norris about suicide.
News
FDA panels back intranasal esketamine for refractory depression
ROCKVILLE, MD –
Mental Health Care Practice
Overemphasizing Communities in the National Strategy for Preventing Veteran Suicide Could Undercut VA Successes
In June 2018, the US Department of Veterans Affairs (VA) issued its National Strategy for Preventing Veteran Suicide, 2018-2028. Its...
News
Comorbid TBI & PTSD raise the risk for sleep disturbances, pain
Conference Coverage
Identifying and stopping a likely mass shooter: A case study
AUSTIN, TEX. – Potential mass shootings that get disrupted offer lessons for prevention.